FTC Warns ‘Junk Patents' Could Make Drugs Like Ozempic Pricier—Here's How

ToplineThe Federal Trade Commission is challenging hundreds of alleged “junk” patent listings filed by several pharmaceutical companies, which regulators claim could increase prices for medications like Novo Nordisk’s diabetes drug Ozempic by making it harder to produce generic drugs.The “bogus” patent listings keep brand name drug prices “artificially high,” regulators said.NurPhoto via Getty Images Key FactsThe FTC sent warning letters to 10 pharmaceutical companies—including Novo Nordisk, AstraZeneca, Gl ...